AlmegaPL CV Health Open Label Study

PHASE4CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

May 11, 2022

Primary Completion Date

November 14, 2022

Study Completion Date

December 1, 2022

Conditions
CholesterolTriglyceridesOmega-3Eicosapentaenoic Acid
Interventions
DIETARY_SUPPLEMENT

AlmegaPL (FDA NDIN # 826)

The investigational product iwi/Cholesterol is a commercially available capsule-form herbal (algae) supplement containing Almega®PL, a Nannochloropsis algae-derived extract rich in eicosapentaenoic acid (EPA). EPA is a type of omega-3 essential fatty acid known to play a beneficial role in protection against cardiovascular disease. Iwi/Cholesterol is the only source of long chain omega-3 that does not contain the DHA that is present in other omega-3 sources (fish oil, krill oil, other algal oils). Almega®PL was registered at the Food and Drug Administration (FDA) as a New Dietary Ingredient (NDIN) in 2014.

Trial Locations (2)

77057

Qualitas Health, Houston

85281

Arizona State University, Tempe

All Listed Sponsors
collaborator

Arizona State University

OTHER

lead

Qualitas Health

INDUSTRY